Holen Sie sich die Stockscreener-App
81.41
1.58%
-1.31
Handel nachbörslich:
83.03
1.62
+1.99%
Schlusskurs vom Vortag:
$82.72
Offen:
$82.93
24-Stunden-Volumen:
456.07K
Relative Volume:
1.23
Marktkapitalisierung:
$1.85B
Einnahmen:
$923.71M
Nettoeinkommen (Verlust:
$84.68M
KGV:
20.65
EPS:
3.9419
Netto-Cashflow:
$182.81M
1W Leistung:
+1.36%
1M Leistung:
+3.52%
6M Leistung:
-3.50%
1J Leistung:
+40.87%
1-Tages-Spanne:
$81.07
$83.75
1-Wochen-Bereich:
$80.67
$83.75
52-Wochen-Spanne:
$57.33
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Firmenname
Ani Pharmaceuticals Inc
Sektor
Telefon
(609) 759-1810
Adresse
104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, MN
Compare ANIP vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
81.41 | 1.88B | 923.71M | 84.68M | 182.81M | 3.9419 |
TAK
Takeda Pharmaceutical Co Adr
|
15.87 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.24 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.61 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.23 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
578.43 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2024-12-11 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-15 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-22 | Bestätigt | H.C. Wainwright | Buy |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-02 | Eingeleitet | Truist | Buy |
| 2020-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-05-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Bestätigt | Canaccord Genuity | Buy |
| 2017-07-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-22 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Eingeleitet | Raymond James | Strong Buy |
| 2016-05-24 | Herabstufung | Standpoint Research | Buy → Hold |
| 2015-11-13 | Eingeleitet | Standpoint Research | Buy |
| 2015-09-28 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-04 | Bestätigt | ROTH Capital | Neutral |
| 2015-07-31 | Bestätigt | Oppenheimer | Outperform |
| 2015-07-15 | Bestätigt | ROTH Capital | Neutral |
| 2015-06-23 | Bestätigt | Oppenheimer | Outperform |
| 2015-05-18 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-04-10 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Bestätigt | ROTH Capital | Buy |
| 2015-02-18 | Bestätigt | Oppenheimer | Outperform |
Alle ansehen
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
ANI Pharmaceuticals raises 2026 revenue outlook to $1.08B-$1.14B while launching $100M share repurchase program - MSN
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Lisanti Capital Growth LLC - MarketBeat
Precision Trading with Ani Pharmaceuticals Inc. (ANIP) Risk Zones - Stock Traders Daily
ANI Pharmaceuticals (ANIP) Q1 earnings: What to expect - MSN
ANI Pharmaceuticals (ANIP) Q1 2026 Earnings: Revenue Beat, Guidance, and Stock DropNews and Statistics - IndexBox
ANI Pharmaceuticals (NASDAQ: ANIP) investors back directors, pay and stock plan - Stock Titan
ANIP Stock Price, Quote & Chart | ANI PHARMACEUTICALS INC (NASDAQ:ANIP) - ChartMill
ANIP News | ANI PHARMACEUTICALS INC (NASDAQ:ANIP) - ChartMill
ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem - Yahoo Finance
ANI Pharmaceuticals Q1 2026 earnings preview - MSN
Profitable Stocks: MYR Group & ANI Pharmaceuticals to Watch, B&G Foods to SellNews and Statistics - IndexBox
ANI Pharmaceuticals (ANIP) shares jump after earnings beat and higher outlook - MSN
How Raised 2026 Guidance And A New Buyback At ANI Pharmaceuticals (ANIP) Has Changed Its Investment Story - Yahoo Finance
ANI Pharmaceuticals Refocuses On Rare Disease As Buybacks And Insider Sales Rise - Yahoo Finance
UBS Group AG Has $11.90 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook - TradingView
ANIP Valuation: Does 9.8x Forward P/E Offer Upside? - TradingView
How ANI’s Raised 2026 Guidance And Buyback Plan At ANI Pharmaceuticals (ANIP) Has Changed Its Investment Story - Sahm
Ani Pharmaceuticals Insider Sold Shares Worth $1,127,120, According to a Recent SEC Filing - Moomoo
ANI Pharmaceuticals(ANIP.US) Officer Sells US$4.27 Million in Common Stock - Moomoo
Insider Sell: Ori Gutwerg Sells Shares of ANI Pharmaceuticals In - GuruFocus
ANI Pharmaceuticals director Walsh sells $1.13m in stock By Investing.com - Investing.com Canada
ANI Pharmaceuticals director Walsh sells $1.13m in stock - Investing.com
ANI Pharmaceuticals (NASDAQ: ANIP) director sells 13,973 shares in open-market trades - Stock Titan
Insider Sell: Meredith Cook Sells 500 Shares of ANI Pharmaceuticals Inc (ANIP) - GuruFocus
Ani Pharmaceuticals President & CEO Sold Shares Worth Over $4.2M - TradingView
[Form 4] ANI PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
ANI Pharmaceuticals (ANIP) CEO sells 55,000 shares at $77.57 average - Stock Titan
ANI Pharmaceuticals (ANIP) SVP sells 2,772 common shares - Stock Titan
ANI Pharmaceuticals (ANIP) legal chief sells 500 shares under 10b5-1 plan - Stock Titan
ANI Pharmaceuticals (ANIP) is a Top-Ranked Momentum Stock: Should You Buy? - sharewise.com
[144] ANI PHARMACEUTICALS INC SEC Filing - Stock Titan
ANI Pharmaceuticals Announces May 2026 Investor Presentation Highlighting Generics Growth and U.S. Manufacturing Footprint - Minichart
ANI Pharmaceuticals Updates Investor Presentation, Highlights Non-GAAP Metrics - TipRanks
ANI Pharmaceuticals projects ~$1.1B 2026 revenue; raises guidance, $100M buyback authorized - TradingView
ANI Pharmaceuticals (NASDAQ: ANIP) targets ~$1.1B in 2026 revenue - Stock Titan
ANI Pharmaceuticals, Inc. $ANIP Shares Purchased by Vanguard Group Inc. - MarketBeat
Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million - Yahoo Finance
Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million - The Motley Fool
Patrick Walsh plans sale of 3,973 ANIP shares (NASDAQ: ANIP) - Stock Titan
ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised - The Globe and Mail
Zacks.com featured highlights include ANI, Cummins and Seadrill - Yahoo Finance
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Perkins Discovery Fund's ANI Pharmaceuticals Inc(ANIP) Holding History - GuruFocus
Is ANI Pharmaceuticals (ANIP) Still Attractively Priced After Recent Pipeline Developments? - Yahoo Finance
ANI Pharmaceuticals Inc (ANIP) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat
MSN Money - MSN
ANI Pharma Q1 2026 slides: rare disease shift drives 20% revenue surge By Investing.com - Investing.com South Africa
ANI Pharma Q1 2026 slides: rare disease shift drives 20% revenue surge - Investing.com Nigeria
ANI Pharmaceuticals, Inc. (ANIP): A Small Cap Value Stock Capitalizing on Generic Drugs Opportunities - Insider Monkey
Finanzdaten der Ani Pharmaceuticals Inc-Aktie (ANIP)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.02%
5.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):